NO890521L - Substituerte pyrimidiner. - Google Patents

Substituerte pyrimidiner.

Info

Publication number
NO890521L
NO890521L NO89890521A NO890521A NO890521L NO 890521 L NO890521 L NO 890521L NO 89890521 A NO89890521 A NO 89890521A NO 890521 A NO890521 A NO 890521A NO 890521 L NO890521 L NO 890521L
Authority
NO
Norway
Prior art keywords
substituted
aryl
formula
trifluoromethyl
alkyl
Prior art date
Application number
NO89890521A
Other languages
English (en)
Norwegian (no)
Other versions
NO890521D0 (no
Inventor
Peter Fey
Rolf Angerbauer
Walter Huebsch
Hilmar Bischoff
Dieter Petzinna
Delf Schmidt
Guenter Thomas
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25865194&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO890521(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE3805913A external-priority patent/DE3805913A1/de
Priority claimed from IT8822721A external-priority patent/IT1227543B/it
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO890521D0 publication Critical patent/NO890521D0/no
Publication of NO890521L publication Critical patent/NO890521L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO89890521A 1988-02-25 1989-02-08 Substituerte pyrimidiner. NO890521L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3805913A DE3805913A1 (de) 1988-02-25 1988-02-25 Substituierte pyrimidine
IT8822721A IT1227543B (it) 1988-11-24 1988-11-24 Pirimidine sostituite.

Publications (2)

Publication Number Publication Date
NO890521D0 NO890521D0 (no) 1989-02-08
NO890521L true NO890521L (no) 1989-08-28

Family

ID=25865194

Family Applications (1)

Application Number Title Priority Date Filing Date
NO89890521A NO890521L (no) 1988-02-25 1989-02-08 Substituerte pyrimidiner.

Country Status (9)

Country Link
EP (1) EP0330057A2 (pt)
JP (1) JPH01261377A (pt)
CN (1) CN1036954A (pt)
AU (1) AU3020289A (pt)
DK (1) DK88989D0 (pt)
FI (1) FI890868A7 (pt)
IL (1) IL89376A0 (pt)
NO (1) NO890521L (pt)
PT (1) PT89809A (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT87929B (pt) * 1987-07-10 1995-03-01 Hoechst Ag Processo para a preparacao de derivados de acido 3-desmetil-mevalonico e de composicoes farmaceuticas que os contem
DE3826814A1 (de) * 1988-08-06 1990-02-08 Hoechst Ag Neue 6-fluor-3,5-dihydroxycarbonsaeuren und deren derivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte
DE3832570A1 (de) * 1988-09-24 1990-03-29 Hoechst Ag 7-substituierte derivate der 3,5-dihydroxyhept-6-insaeure, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
EP0705837B1 (en) 1994-09-06 2002-08-07 Ube Industries, Ltd. Preparation of 3-Oxy-5-oxo-6-heptenoic acid derivatives
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
TW200614993A (en) * 2004-06-11 2006-05-16 Akzo Nobel Nv 4-phenyl-pyrimidine-2-carbonitrile derivatives
US8372877B2 (en) 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
EP2626069A4 (en) 2010-10-06 2014-03-19 Univ Tokyo Prophylactic and/or therapeutic agent against lymphedema
EP3184103A1 (en) 2015-12-21 2017-06-28 Hexal AG Pharmaceutical composition comprising atorvastatin or a salt thereof

Also Published As

Publication number Publication date
DK88989D0 (da) 1989-02-24
FI890868A7 (fi) 1989-08-26
NO890521D0 (no) 1989-02-08
IL89376A0 (en) 1989-09-10
FI890868A0 (fi) 1989-02-23
AU3020289A (en) 1989-08-31
CN1036954A (zh) 1989-11-08
PT89809A (pt) 1989-10-04
EP0330057A2 (de) 1989-08-30
JPH01261377A (ja) 1989-10-18

Similar Documents

Publication Publication Date Title
KR0132432B1 (ko) 치환 피리딘
EP0235164B1 (en) Imidazole analogs of mevalonolactone and derivatives thereof
KR900001212B1 (ko) 메바로노락톤 및 그것의 유도체의 헤테로사이클릭 유사체 및 그것의 생산방법 및 약학적인 그것의 용도
IE893987L (en) Substituted 2-pyridones and pyrid-2-thiones, processes for¹their preparation and their use in medicaments
CZ290093A3 (en) Hexahydronaphthalene ester derivatives, process of their preparation and pharmaceutical preparations in which they are comprised
CA2046734A1 (en) Substituted pyrrolo-pyridines pharmaceuticals
NO881411L (no) Substituerte pyrroler.
NO890521L (no) Substituerte pyrimidiner.
JP2712107B2 (ja) 二置換ピリジン類
JPH01272584A (ja) 5―置換1H―ピラゾロ[3,4―b]ピリジン誘導体、その製法と薬学的組成物
EP0312269B1 (en) 3,5-dihydroxy-6,8-nonadienoic acids and derivatives as hypocholesterolemic agents
KR900009006B1 (ko) 메발로락톤의 동족체 및 그것의 유도체의 제조방법
US4829081A (en) Analogs of mevalonolactone and derivatives thereof
NO885117L (no) Substituerte hydroksylaminer.
HU212304B (en) Process for producing oxophtalazinyl acetic acid derivatives
US5137881A (en) Substituted pyrido-oxazine inhibitors of hmg-coa reductase
US4988711A (en) HMG-CoA reductare-inhibiting N-substituted N-amino-pyrroles
US5138090A (en) Substituted biphenyls
US4937255A (en) Disubstituted pyrroles
IE902802A1 (en) Imino-substituted pyridines
NZ235144A (en) Substituted amino pyridine derivatives, intermediates and pharmaceutical compositions thereof
NZ228087A (en) Imidazolinone derivatives; pharmaceutical compositions and preparatory processes
KR870000313B1 (ko) 6-(아미노메틸)페니실란산 1,1-다이옥사이드 및 이의 유도체의 제조방법
CA2224211A1 (en) Syntheses of optically pure compounds useful as garft inhibitors and their intermediates
DE3805913A1 (de) Substituierte pyrimidine